396 related articles for article (PubMed ID: 30190462)
1. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
[TBL] [Abstract][Full Text] [Related]
2. Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
Xie JJ; Jiang YY; Jiang Y; Li CQ; Lim MC; An O; Mayakonda A; Ding LW; Long L; Sun C; Lin LH; Chen L; Wu JY; Wu ZY; Cao Q; Fang WK; Yang W; Soukiasian H; Meltzer SJ; Yang H; Fullwood M; Xu LY; Li EM; Lin DC; Koeffler HP
Gastroenterology; 2018 Jun; 154(8):2137-2151.e1. PubMed ID: 29454790
[TBL] [Abstract][Full Text] [Related]
3. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
[TBL] [Abstract][Full Text] [Related]
4. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
[TBL] [Abstract][Full Text] [Related]
5. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.
Watanabe H; Ma Q; Peng S; Adelmant G; Swain D; Song W; Fox C; Francis JM; Pedamallu CS; DeLuca DS; Brooks AN; Wang S; Que J; Rustgi AK; Wong KK; Ligon KL; Liu XS; Marto JA; Meyerson M; Bass AJ
J Clin Invest; 2014 Apr; 124(4):1636-45. PubMed ID: 24590290
[TBL] [Abstract][Full Text] [Related]
6. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.
Sato T; Yoo S; Kong R; Sinha A; Chandramani-Shivalingappa P; Patel A; Fridrikh M; Nagano O; Masuko T; Beasley MB; Powell CA; Zhu J; Watanabe H
Cancer Res; 2019 Dec; 79(24):6084-6100. PubMed ID: 31551362
[TBL] [Abstract][Full Text] [Related]
7. Activation of bivalent factor DLX5 cooperates with master regulator TP63 to promote squamous cell carcinoma.
Huang Y; Yang Q; Zheng Y; Lin L; Xu X; Xu XE; Silva TC; Hazawa M; Peng L; Cao H; Ding Y; Lu D; Berman BP; Xu LY; Li EM; Yin D
Nucleic Acids Res; 2021 Sep; 49(16):9246-9263. PubMed ID: 34370013
[TBL] [Abstract][Full Text] [Related]
8. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
Hegde GV; de la Cruz C; Giltnane JM; Crocker L; Venkatanarayan A; Schaefer G; Dunlap D; Hoeck JD; Piskol R; Gnad F; Modrusan Z; de Sauvage FJ; Siebel CW; Jackson EL
Elife; 2019 May; 8():. PubMed ID: 31144617
[TBL] [Abstract][Full Text] [Related]
9. p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas.
Hsieh MH; Choe JH; Gadhvi J; Kim YJ; Arguez MA; Palmer M; Gerold H; Nowak C; Do H; Mazambani S; Knighton JK; Cha M; Goodwin J; Kang MK; Jeong JY; Lee SY; Faubert B; Xuan Z; Abel ED; Scafoglio C; Shackelford DB; Minna JD; Singh PK; Shulaev V; Bleris L; Hoyt K; Kim J; Inoue M; DeBerardinis RJ; Kim TH; Kim JW
Cell Rep; 2019 Aug; 28(7):1860-1878.e9. PubMed ID: 31412252
[TBL] [Abstract][Full Text] [Related]
10. A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer.
Liu Y; Wu Z; Zhou J; Ramadurai DKA; Mortenson KL; Aguilera-Jimenez E; Yan Y; Yang X; Taylor AM; Varley KE; Gertz J; Choi PS; Cherniack AD; Chen X; Bass AJ; Bailey SD; Zhang X
Nat Commun; 2021 Dec; 12(1):7139. PubMed ID: 34880227
[TBL] [Abstract][Full Text] [Related]
11. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling.
Wei CX; Wong H; Xu F; Liu Z; Ran L; Jiang RD
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8169-8178. PubMed ID: 30556855
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
13. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.
Yi M; Tan Y; Wang L; Cai J; Li X; Zeng Z; Xiong W; Li G; Li X; Tan P; Xiang B
Cell Mol Life Sci; 2020 Nov; 77(21):4325-4346. PubMed ID: 32447427
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
[TBL] [Abstract][Full Text] [Related]
15. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
[TBL] [Abstract][Full Text] [Related]
16. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis.
Hu M; Zhang Q; Tian XH; Wang JL; Niu YX; Li G
Mol Carcinog; 2019 Dec; 58(12):2207-2217. PubMed ID: 31544294
[TBL] [Abstract][Full Text] [Related]
17. SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma.
Chai Y; Li Q; Zhao H; Zhang Z; Yu X; Pang L; Liu Z; Zhao J; Wang L; Li F
Cancer Med; 2019 Nov; 8(16):7055-7064. PubMed ID: 31560173
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
19. LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases.
Herrera-Solorio AM; Peralta-Arrieta I; Armas López L; Hernández-Cigala N; Mendoza Milla C; Ortiz Quintero B; Catalán Cárdenas R; Pineda Villegas P; Rodríguez Villanueva E; Trejo Iriarte CG; Zúñiga J; Arrieta O; Ávila-Moreno F
Mol Oncol; 2021 Apr; 15(4):1110-1129. PubMed ID: 33433063
[TBL] [Abstract][Full Text] [Related]
20. CCAT1/FABP5 promotes tumour progression through mediating fatty acid metabolism and stabilizing PI3K/AKT/mTOR signalling in lung adenocarcinoma.
Chen J; Alduais Y; Zhang K; Zhu X; Chen B
J Cell Mol Med; 2021 Oct; 25(19):9199-9213. PubMed ID: 34431227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
